Understanding the Differences Between Ointments, Creams, and Gels in Semi-Solid Drug Products

Defining Ointments, Creams, and Gels in Pharmaceutical Development

In topical and ophthalmic drug development, one of the earliest formulation decisions is the selection of an appropriate semi-solid dosage form. The most common options—ointments, creams, and gels—represent distinct formulation categories, each engineered to address specific therapeutic, patient, and regulatory needs. Understanding the differences between ointment vs cream vs gel is critical for formulation scientists and development teams, as this choice affects drug delivery, stability, manufacturing, and patient experience.

Ointments are generally hydrophobic (oil-based) systems, characterized by their high occlusivity and ability to form a protective layer over the application site. Creams are typically emulsions, containing both oil and water phases, and offer a balance between spreadability and moisturizing effect. Gels are semi-solid systems, usually based on hydrophilic polymers that create a clear or translucent matrix capable of holding active pharmaceutical ingredients (APIs) in a water-based medium.

Each of these semi-solid drug products has unique advantages and limitations. Choosing the right base is not only a matter of physical appearance or patient preference—it is a technical decision influencing API solubility, release kinetics, stability, and even the clinical performance of the finished product. At Dow Development Labs (DDL), our team regularly guides clients through these critical formulation choices, drawing on experience with a wide range of topical and ophthalmic drug candidates.

In the following sections, we’ll examine the key formulation differences, clinical implications, and regulatory considerations associated with ointment vs cream vs gel, providing a clear framework for pharmaceutical and biotech teams tackling semi-solid development challenges.

Key Formulation Differences: Ointment vs Cream vs Gel

The fundamental distinctions between ointments, creams, and gels stem from their composition, physicochemical properties, and intended use. Each formulation type is designed to meet specific criteria regarding API compatibility, patient acceptability, and overall performance. The table below summarizes the key formulation differences and practical attributes of ointment vs cream vs gel:

For further reading, see Comparison of lotions, creams, gels and ointments for the treatment from the National Institutes of Health.

These differences are not merely cosmetic. For example, a hydrophobic ointment may be preferred for chronic plaque psoriasis to maximize occlusion, while a gel may be indicated for acne treatment where rapid absorption and a non-greasy feel are desired. The ability to match the formulation to both the physicochemical properties of the API and the target patient population is a core function of pharmaceutical development programs at DDL and across the industry.

Occlusivity and Absorption: How Base Type Impacts Drug Delivery

Occlusivity—the ability of a topical formulation to form a barrier and reduce transepidermal water loss—is a defining characteristic that differentiates ointments, creams, and gels. This property not only affects patient perception but can significantly influence drug delivery to and through the skin.

• Ointments provide the highest occlusivity, forming a semi-impermeable film that can hydrate the stratum corneum, enhance drug penetration, and protect wounds or sensitive areas. This is especially important for APIs that benefit from prolonged skin contact, such as corticosteroids used in chronic eczema.
• Creams offer moderate occlusive properties, depending on the ratio of oil to water and the presence of emulsifiers. They are often selected for conditions requiring both hydration and breathability, such as mild dermatitis or post-procedure skin care.
• Gels are generally non-occlusive, allowing for rapid evaporation of water and fast drug release. This makes gels ideal for conditions where a cooling effect is desired, or for APIs that require rapid absorption without significant skin barrier modification (e.g., topical NSAIDs for acute musculoskeletal pain).

Formulation scientists must consider the impact of the base type not only on the rate and extent of drug absorption but also on the potential for irritation, patient adherence, and the intended site of action. For ophthalmic drugs, for example, ointments may extend contact time with the ocular surface but can transiently blur vision, while gels and creams offer different balances of retention and tolerability. DDL’s development programs are designed to account for these nuanced considerations, working closely with sponsors to optimize drug delivery for each indication and patient population.

Stability Considerations Unique to Each Semi-Solid Formulation

The physical and chemical stability profiles of ointments, creams, and gels are shaped by their distinct compositions. Understanding these differences is essential for robust formulation development and successful regulatory submissions.

• Ointments typically exhibit excellent physical stability due to their low water content, minimizing risks of microbial growth and hydrolytic degradation. However, oxidative degradation of unsaturated oils or active ingredients remains a concern, requiring careful selection of antioxidants and packaging materials.
• Creams are inherently less stable given their emulsion nature. Phase separation, creaming, and microbial contamination are common challenges, particularly for oil-in-water systems. The inclusion of appropriate preservatives and rigorous process controls during manufacturing are essential to ensure product quality over shelf life.
• Gels may be prone to syneresis (water separation), viscosity changes, and pH drift, depending on the polymeric gelling agents used and the presence of electrolytes or other excipients. Preservative efficacy testing and rheological measurements are especially important for gels intended for long-term storage.

For all semi-solid drug products, ICH stability guidelines recommend monitoring not just API potency but also physical attributes such as appearance, texture, and homogeneity. At Dow Development Labs, our approach to stability studies includes tailored protocols for each formulation type, supporting data generation for IND, NDA, or ANDA filings as required by regulatory authorities.

Patient Experience and Clinical Use: When to Choose Ointment, Cream, or Gel

The choice between ointment vs cream vs gel has a direct impact on patient adherence and clinical outcomes. Patient-centric factors, such as ease of application, sensory properties, and cosmetic acceptability, are increasingly recognized as critical to therapeutic success—especially in dermatology and ophthalmology.

1. Ointments are typically reserved for conditions where maximum hydration and barrier protection are needed, such as chronic eczema, burns, or dry eye syndromes. Their greasy residue may reduce patient compliance for use on exposed skin or during daytime activities.
2. Creams strike a balance between efficacy and user acceptability. They are widely used for acute and subacute dermatoses, post-surgical wound care, or as vehicles for antifungals, antibiotics, and corticosteroids. Creams are often preferred for facial or intertriginous areas due to their lighter feel.
3. Gels are favored for their fast absorption, cooling effect, and non-greasy finish. They are often selected for the delivery of topical NSAIDs, acne medications, or ophthalmic drugs where minimal interference with vision or tactile sensation is required.

Clinical decision-making is rarely one-size-fits-all. The same API may be formulated as an ointment, cream, or gel for different indications or patient groups. Dow Development Labs works collaboratively with sponsors to evaluate these factors during early-phase development, helping to align formulation selection with both clinical objectives and patient needs.

Ointment vs Cream vs Gel: Regulatory and Manufacturing Considerations

Regulatory and manufacturing requirements for ointments, creams, and gels share many commonalities, but each category also presents unique challenges that can affect program timelines and risk profiles.

• Ointments are generally simpler to manufacture, often requiring only mixing and homogenization at controlled temperatures. However, their high viscosity can complicate filling and packaging, particularly for ophthalmic presentations.
• Creams require precise control over emulsification processes to ensure batch-to-batch uniformity and long-term physical stability. Critical process parameters include mixing speed, temperature, and the order of ingredient addition.
• Gels demand careful choice and handling of gelling agents to achieve the desired rheological properties. Some polymers are sensitive to shear, pH, or ionic strength, which must be tightly managed during scale-up and commercial manufacturing.

From a regulatory standpoint, FDA and ICH guidelines emphasize the demonstration of equivalence in generic development, particularly for topical semisolids under the 505(j) pathway. For new drug applications, comprehensive characterization of the formulation and process is critical. Analytical method development, process validation, and container-closure compatibility studies are central to DDL’s development services for ointment, cream, and gel programs, designed to support robust CMC submissions.

Analytical and Stability Testing Approaches for Semi-Solid Drug Products

Effective analytical and stability testing is essential for the development and lifecycle management of semi-solid pharmaceuticals. The complexity of ointments, creams, and gels requires specialized methodologies and a nuanced understanding of product attributes.

• API Assay and Content Uniformity: Ensuring accurate and reproducible delivery of the API across multiple doses and containers is fundamental, especially for products intended for topical or ophthalmic use. Homogeneity testing is a regulatory expectation for all dosage units.
• Physical Characterization: Rheological measurements (viscosity, yield stress), particle size analysis (for suspended APIs), and microscopic examination are used to monitor batch consistency and detect formulation drift over time.
• Microbial Testing: Especially critical for creams and gels with higher water activity, preservative efficacy and bioburden assessments are routinely performed.
• In Vitro Release Testing (IVRT): Regulatory agencies increasingly expect IVRT data to support bioequivalence claims and formulation comparability assessments, particularly for generic semisolid drugs.
• Stability Studies: ICH Q1A(R2) guidelines direct the design of long-term and accelerated stability protocols, with monitoring for physical, chemical, and microbiological endpoints.

At Dow Development Labs, our analytical and stability testing capabilities are designed to meet industry and regulatory expectations for semi-solid drug products. Our experience spans method development, validation, and execution of stability studies to support IND, NDA, and ANDA submissions.

Partnering for Semi-Solid Drug Product Development: How DDL Supports Ointment, Cream, and Gel Programs

Selecting the right formulation partner is a pivotal decision for biotech and pharmaceutical companies pursuing topical or ophthalmic drug development. Dow Development Labs, based in Petaluma, CA, brings deep expertise in the design, development, and analytical characterization of ointments, creams, and gels. Our integrated approach is designed to support clients from early feasibility through to clinical supply manufacturing and regulatory submission.

• Collaborative Formulation Development: DDL works closely with sponsors to evaluate the suitability of ointment, cream, and gel formulations for specific APIs, indications, and patient populations.
• Analytical and Stability Services: We offer comprehensive method development, validation, and stability testing tailored to the unique challenges of semi-solid drug products.
• cGMP Manufacturing: Our facilities support clinical-scale manufacturing of topical and ophthalmic ointments, creams, and gels under current Good Manufacturing Practices, with a focus on quality and regulatory compliance.
• Regulatory Support: DDL assists clients in preparing CMC documentation and addressing regulatory expectations for semi-solid products throughout the development lifecycle.

Whether you are seeking to advance a novel API or develop a generic semi-solid drug product, DDL’s experience and client-focused approach can help navigate the complexities of formulation selection, analytical testing, and regulatory submission. To discuss your ointment, cream, or gel development needs, contact Dow Development Labs at 707-202-6965 and discover how our team can support your program’s success.